Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease

Proteomics - Clinical Applications

Volumn 1, Issue 11, 2007, Pages 1373-1384

  Hu, Yan ^a   Hosseini, Ava ^a   Kauwe, John S K ^a   Gross, Julia ^a   Cairns, Nigel J ^a   Goate, Alison M ^a   Fagan, Anne M ^a   Townsend, R Reid ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 D DIGE; Alzheimer's disease; Biomarker; Cerebrospinal fluid

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA1 GLYCOPROTEIN; AMYLOID BETA PROTEIN[1-42]; ANGIOTENSINOGEN; ANTITHROMBIN III; BETA TRACE; BIOLOGICAL MARKER; BRAIN PROTEIN; CARNOSINASE 1; CHROMAGRANIN B; GELSOLIN; KININOGEN; PENTRAXIN; PROSTAGLANDIN D2; PROSTAGLANDIN D2 SYNTHASE; SECRETOGRANIN III; TAU PROTEIN; UNCLASSIFIED DRUG; ZINC ALPHA1 GLYCOPROTEIN;

ALZHEIMER DISEASE; ARTICLE; CELLULAR DISTRIBUTION; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL ELECTROPHORESIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

EID: 38449092906     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200600999     Document Type: Article

References (49)

1. Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., Evans, D. A., State-specific projections through 2025 of Alzheimer disease prevalence. Neurology 2004, 62, 1645.
2. Morris, J. C., Price, A. L., Pathologic correlates of non-demented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci. 2001, 17, 101-118.
3. Morris, J. C., Storandt, M., Miller, J. P., McKeel, D. W. et al., Mild cognitive impairment represents early-stage Alzheimer disease. Arch. Neurol. 2001, 58, 397-405.
4. Blennow, K., Wallin, A., Hager, O., Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol. Scand. 1993, 88, 221-223.
5. Andreasen, N., Sjogren, M., Blennow, K., CSF markers for Alzheimer's disease: Total tau, phospho-tau and Abeta42. World J. Biol. Psychiatry 2003, 4, 147-155.
6. Sunderland, T., Linker, G., Mirza, N., Putnam, K. T. et al., Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003, 289, 2094-2103.
7. Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S. Y. et al., Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59, 512-519.
8. Hansson, O., Zetterberg, H., Buchhave, P., Londos, E. et al., Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol. 2006, 5, 228-234.
9. Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A. et al., Cerebrospinal fluid tau/beta-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 2007, 64, 343-349.
10. Abdi, F., Quinn, J. F., Jankovic, J., McIntosh, M. et al., Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 2006, 9, 293-348.
11. Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O. et al., A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003, 3, 1486-1494.
12. Castano, E. M., Roher, A. E., Esh, C. L., Kokjohn, T. A., Beach, T., Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and nondemented elderly subjects. Neurol. Res. 2006, 28, 155-163.
13. Choe, L. H., Dutt, M. J., Relkin, N., Lee, K. H., Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis 2002, 23, 2247-2251.
14. Davidsson, P., Westman-Brinkmalm, A., Nilsson, C. L., Lindbjer, M. et al., Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 2002, 13, 611-615.
15. Puchades, M., Hansson, S. F., Nilsson, C. L., Andreasen, N. et al., Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res. Mol. Brain Res. 2003, 118, 140-146.
16. Wittke, S., Mischak, H., Walden, M., Kolch, W. et al., Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: Towards new diagnostic and therapeutic approaches. Electrophoresis 2005, 26, 1476-1487.
17. Zhang, J., Goodlett, D. R., Quinn, J. F., Peskind, E. et al., Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis. 2005, 7, 125-133.
18. Hu, Y., Malone, J. P., Fagan, A. M., Townsend, R. R., Holtzman, D. M., Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol. Cell. Proteomics 2005, 4, 2000-2009.
19. Berg, L., McKeel, D. W., Jr., Miller, J. P., Storandt, M. et al., Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol. 1998, 55, 326-335.
20. Morris, J. C., McKeel, D. W., Jr., Fulling, K., Torack, R. M., Berg, L., Validation of clinical diagnostic criteria for Alzheimer's disease. Ann. Neurol. 1988, 24, 17-22.
21. Fagan, A. M., Younkin, L. H., Morris, J. C., Fryer, J. D. et al., Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann. Neurol. 2000, 48, 201-210.
22. Havlis, J., Thomas, H., Sebela, M., Shevchenko, A., Fast-response proteomics by accelerated in-gel digestion of proteins. Anal. Chem. 2003, 75, 1300-1306.
23. Bredemeyer, A. J., Lewis, R. M., Malone, J. P., Davis, A. E. et al., A proteomic approach for the discovery of protease substrates. Proc. Natl. Acad. Sci. USA 2004, 101, 11785-11790.
24. King, J. B., Gross, J., Lovly, C. M., Rohrs, H. et al., Accurate mass-driven analysis for the characterization of protein phosphorylation. Study of the human Chk2 protein kinase. Anal. Chem. 2006, 78, 2171-2181.
25. Sing, T., Sander, O., Beerenwinkel, N., Lengauer, T., ROCR: Visualizing classifier performance in R. Bioinformatics 2005, 21, 3940-3941.
26. Xiong, C., McKeel, D. W., Jr., Miller, J. P., Morris, J. C., Combining correlated diagnostic tests: Application to neuropathologic diagnosis of Alzheimer's disease. Med. Decis. Making 2004, 24, 659-669.
27. Han, B. H., D'Costa, A., Back, S. A., Parsadanian, M. et al., BDNF blocks caspase-3 activation in neonatal hypoxiaischemia. Neurobiol. Dis. 2000, 7, 36-53.
28. Bales, K. R., Verina, T., Dodel, R. C., Du, Y. et al., Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 1997, 17, 263.
29. Abraham, C. R., Selkoe, D. J., Potter, H., Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988, 52, 487-501.
30. Abraham, C. R., Shirahama, T., Potter, H., Alpha 1-antic-hymotrypsin is associated solely with amyloid deposits containing the beta-protein. Amyloid and cell localization of alpha 1-antichymotrypsin. Neurobiol. Aging 1990, 11, 123-129.
31. Kalaria, R. N., Golde, T., Kroon, S. N., Perry, G., Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer's disease. Am. J. Pathol. 1993, 143, 886-893.
32. Gimenez-Roqueplo, A. P., Celerier, J., Lucarelli, G., Corvol, P., Jeunemaitre, X., Role of N-glycosylation in human angiotensinogen. J. Biol. Chem. 1998, 273, 21232-21238.
33. Matsubara, E., Hirai, S., Amari, M., Shoji, M. et al., Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann. Neurol. 1990, 28, 561-567.
34. DeKosky, S. T., Ikonomovic, M. D., Wang, X., Farlow, M. et al., Plasma and cerebrospinal fluid alpha 1-antichymotrypsin levels in Alzheimer's disease: Correlation with cognitive impairment. Ann. Neurol. 2003, 53, 81-90.
35. Harigaya, Y., Shoji, M., Nakamura, T., Matsubara, E. et al., Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease. Intern. Med. 1995, 34, 481-484.
36. Licastro, F., Parnetti, L., Morini, M. C., Davis, L. J. et al., Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1995, 9, 112-118.
37. Pirttila, T., Mehta, P. D., Frey, H., Wisniewski, H. M., Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. Neurobiol. Aging 1994, 15, 313-317.
38. Licastro, F., Masliah, E., Pedrini, S., Thal, L. J., Blood levels of alpha-l-antichymotrypsin and risk factors for Alzheimer's disease: Effects of gender and apolipoprotein E genotype. Dement. Geriatr. Cogn. Disord. 2000, 11, 25-28.
39. Lanzrein, A. S., Johnston, C. M., Perry, V. H., Jobst, K. A. et al., Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: Interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis. Assoc. Disord. 1998, 12, 215-227.
40. Oishi, M., Mochizuki, Y., Yoshihashi, H., Takasu, T., Nakano, E., Laboratory examinations correlated with severity of dementia. Ann. Clin. Lab. Sci. 1996, 26, 340-345.
41. Licastro, F., Pedrini, S., Caputo, L., Annoni, G. et al., Increased plasma levels of interleukin-1, interleukin-6 and alpha-l-antichymotrypsin in patients with Alzheimer's disease: Peripheral inflammation or signals from the brain? J. Neuroimmunol. 2000, 103, 97-102.
42. Mrak, R. E., Sheng, J. G., Griffin, W. S., Glial cytokines in Alzheimer's disease: Review and pathogenic implications. Hum. Pathol. 1995, 26, 816-823.
43. Deschepper, C. F., Bigornia, V., Berens, M. E., Lapointe, M. C., Production of thrombin and antithrombin III by brain and astroglial cell cultures. Brain Res. Mol. Brain Res. 1991, 11, 355-358.
44. Pasternack, J. M., Abraham, C. R., Van Dyke, B. J., Potter, H., Younkin, S. G., Astrocytes in Alzheimer's disease gray matter express alpha 1-antichymotrypsin mRNA. Am. J. Pathol. 1989, 135, 827-834.
45. Poortmans, J. R., Schmid, K., The level of Zn-alpha 2-glycoprotein in normal human body fluids and kidney extract. J. Lab. Clin. Med. 1968, 71, 807-811.
46. Diez-Itza, I., Sanchez, L. M., Allende, M. T., Vizoso, F. et al., Zn-alpha 2-glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters. Eur. J. Cancer 1993, 294, 1256-1260.
47. Teufel, M., Saudek, V., Ledig, J. P., Bernhardt, A. et al., Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J. Biol. Chem. 2003, 278, 6521-6531.
48. Wassif, W. S., Sherwood, R. A., Amir, A., Idowu, B. et al., Serum carnosinase activities in central nervous system disorders. Clin. Chim. Acta 1994, 225, 57-84.
49. Finehout, E. J., Franck, Z., Choe, L. H., Relkin, N., Lee, K. H., Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann. Neurol. 2006, 61, 120-129.